BEAM vs SHC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BEAM and SHC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BEAM and SHC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both strands of the double helix, aiming for more precise fixes than first-generation CRISPR. Its pipeline spans risto-cel (formerly BEAM-101) for sickle cell disease, with a biologics license application targeted as early as year-end 2026, plus BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 and BEAM-304 for rare liver-mediated genetic diseases. The company also runs collaborations with partners including Pfizer and Eli Lilly, which supply most of its reported revenue through upfront payments and milestones.

Full BEAM guide

Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to June 30, 2026 was ~$1.22 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle.

Full SHC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BEAM drivers: Risto-cel sickle cell path to filing; In vivo liver franchise.
• SHC drivers: Contracted volume and repeat pricing; Nordion's cobalt-60 position and the harvest cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. For SHC, the ethylene oxide tort docket is the dominant, partly quantified risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BEAM if you believe its drivers more; SHC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BEAM and SHC guides.

BEAM. Beam's revenue is collaboration and milestone income, not product sales, so it is lumpy and not comparable to a profitable company's top line. With no approved therapy and heavy R&D spending, the company runs large net losses funded by its cash pile. Valuation therefore reflects the market's probability-weighted view of the pipeline rather than current earnings.

SHC. Roughly 12x enterprise value to adjusted EBITDA is a modest price for a business earning 51% EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation. Sotera carries no reserve for the ~970 ethylene oxide claims still outstanding, so the multiple embeds an unpriced tail rather than a known cost. The trailing GAAP P/E of ~34x, meanwhile, reflects amortization, interest and settlement charges that the adjusted figures strip out.

Headline figures (approximate, MAY 2026): BEAM shows market cap ~$3.6B, revenue (q1 2026) ~$31.7M, revenue (q1 2025) ~$7.5M, net loss (q1 2026) ~$94.3M; SHC shows revenue (ttm) ~$1.22 billion for the twelve months to June 30, 2026, up ~8% from ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Second-quarter 2026 revenue was $321.4 million, up 9.2% year over year and 8.0% in constant currency. On August 6, 2026 management raised full-year guidance to $1.236 billion to $1.254 billion, implying 5.25% to 6.75% constant-currency growth plus an estimated 100 basis points of currency benefit., earnings and eps GAAP net income of ~$163.5 million for the twelve months to June 30, 2026, against $77.9 million in fiscal 2025 and $44.3 million in fiscal 2024. Trailing diluted EPS is $0.57, putting the shares near 34x reported earnings. The year-on-year comparison flatters 2026 because fiscal 2025 absorbed $64.9 million of Illinois settlement charges and heavier intangible amortization. Q2 2026 net income was $53.6 million ($0.19 diluted) versus $8.0 million ($0.03) a year earlier; adjusted EPS of $0.26 rose 30%, and full-year adjusted EPS guidance is $0.95 to $1.01., segment mix and margins For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In the second quarter of 2026 those revenues were $211.6 million, $49.1 million and $60.7 million, with segment income of $118.1 million, $28.0 million and $19.6 million. Consolidated adjusted EBITDA margin was 51.6% in the quarter and 51.1% on a trailing twelve-month basis. Nelson Labs is the swing factor, having fallen 3.9% in 2025., cash flow and capital spending Net cash from operating activities was $117.9 million in the first half of 2026 versus $112.9 million a year earlier, with $88 million of it in the second quarter. Capital expenditure was $92.6 million in the half against $51.1 million in the prior-year half, and full-year 2026 guidance is $200 million to $225 million, close to 17% of revenue. Free cash flow is therefore a small fraction of the $621.6 million of trailing adjusted EBITDA, because cobalt supply, plant capacity and emissions controls all consume cash..

BEAM and SHC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BEAM and SHC exposure against your real portfolio. It is not an investment adviser.